AI assistant
Moderna, Inc. — Director's Dealing 2022
Jun 21, 2022
30610_dirs_2022-06-21_cdbcddc3-85b9-4a14-850d-3046791e2866.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2022-06-16
Reporting Person: Burton Paul (Chief Medical Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-06-16 | Stock Option (Right to Buy) | $121.08 | A | 6902 | Acquired | 2032-06-16 | Common Stock (6902) | Direct |
| 2022-06-16 | Restricted Stock Units | $0 | A | 3663 | Acquired | Common Stock (3663) | Direct | |
| 2022-06-16 | Stock Option (Right to Buy) | $121.08 | A | 19772 | Acquired | 2032-06-16 | Common Stock (19772) | Direct |
| 2022-06-16 | Restricted Stock Units | $0 | A | 10990 | Acquired | Common Stock (10990) | Direct |
Footnotes
F1: 25% of this option will vest and become exercisable on June 16, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
F2: 25% of the shares subject to this restricted stock unit award will vest on June 16, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
F3: 50% of this option will vest and become exercisable on June 16, 2025 and the remaining 50% will vest and become exercisable on June 16, 2026, subject to the recipient's continued service.
F4: 50% of the shares subject to this restricted stock unit award will vest on June 16, 2025 and the remaining 50% will vest on June 16, 2026, subject to the recipient's continued service.